A Phase 3 interventional study of VK2735 in Weight Loss, sponsored by Viking Therapeutics, Inc.. Active, not recruiting at 137 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Viking Therapeutics, Inc. · Phase 3, Interventional, and Treatment
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
1,766 studies on the registry are indexed under Weight Loss; 277 are open to participants now.
This study's planned enrollment of 4,500 is above the median of 73 across 1,496 interventional studies indexed under Weight Loss.
Browse Weight Loss studies →Viking Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)
Exclusion Criteria:
VK2735 Placebo Comparator Once Weekly
Drug: VK2735
VK2735 7.5mg Once Weekly
Drug: VK2735
VK2735 12.5mg Once Weekly
Drug: VK2735
VK2735 17.5mg Once Weekly
Drug: VK2735
VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly
Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment
Time frame: 78 Weeks
Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment
Time frame: 78 Weeks
Showing the first 100 of 137 sites across 2 countries.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Viking Therapeutics, Inc.